Re: BREAKING NEWS: Tradjenta fails to enter German market, now to be pulled from the
Don't get all freaked out. The news clips says:
"Germany's Institute for Quality and Efficiency in Health Care (IQWiG) reassessed Trajenta linagliptin from Boehringer Ingelheim GmbH (Ingelheim, Germany) and said the diabetes drug provides "no additional benefit" over sulfonylurea, a comparator requested by Germany's Federal Joint Committee (G-BA). Boehringer said it sees a "clear additional benefit" for the dipeptidyl peptidase-4 (DPP-4) inhibitor and will submit a response to G-BA by Dec. 24. A final benefit assessment from G-BA is expected in late February 2013."
Boehringer's resubmission included a comparison between Trajenta and a sulfonylurea, but IQWiG said the study was "not suited" for determining the additional benefit for Trajenta because doses of the sulfonylurea glimepiride were adjusted in the trial until patients reached a certain HbA1c value, while doses of Trajenta were not adjusted.
Not a big deal...relax!